LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Study Shows Curcumin Kills Childhood Neuroblastoma Cells

By LabMedica International staff writers
Posted on 08 Aug 2017
Treatment-resistant human childhood neuroblastoma tumor cells growing in culture were targeted and destroyed by the natural anti-cancer agent curcumin, which had been delivered to the cells via a novel class of cerium oxide nanoparticles.

Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys with most cases appearing in children younger than five years old. High-risk neuroblastoma is difficult to treat and frequently develops resistance to standard therapies or recurs.

Investigators at the University of Central Florida (Orlando, USA) synthesized various formulations of nanoceria (cerium oxide nanoparticles) and dextran-coated nanoceria loaded with curcumin. Curcumin is known to have substantial anti-cancer properties, but its low solubility and poor stability have reduced its usefulness in medicinal applications.

In the current study, the anti-cancer activities of the nanoparticle formulations were explored in neuroblastoma models of both MYCN (N-myc proto-oncogene protein)-amplified and non-amplified cell lines. Amplification and overexpression of N-Myc can lead to tumorigenesis. Excess N-Myc is associated with a variety of tumors, most notably neuroblastomas where patients with amplification of the N-Myc gene tend to have poor outcomes.
Results published in the June 9, 2017, online edition of the journal Nanoscale revealed that ceria nanoparticles, coated with dextran and loaded with curcumin, induced substantial cell death in neuroblastoma cells while producing no or only minor toxicity in healthy cells. This formulation evoked prolonged oxidative stress and induced caspase-dependent apoptosis. Overall, nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.

"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs," said senior author Dr. Sudipta Seal, professor of materials science at the University of Central Florida. "More research is needed, but we are hopeful it could lead to more effective treatment of this devastating disease in the future."

Related Links:
University of Central Florida

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more